These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2372673)
21. The prognostic significance of ploidy and DNA-heterogeneity in the primary diagnosis and monitoring of patients with locally advanced prostatic carcinoma. Nagel R; al Abadi H Scand J Urol Nephrol Suppl; 1991; 138():83-92. PubMed ID: 1785025 [TBL] [Abstract][Full Text] [Related]
22. [Clinical studies on endocrine therapy of prostatic carcinoma (1): Multivariate analyses of prognostic factors in patients with prostatic carcinoma given endocrine therapy]. Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Ohshima H; Takeuchi H; Yoshida O; Okada K; Saito Y Hinyokika Kiyo; 1990 Mar; 36(3):275-84. PubMed ID: 2191569 [TBL] [Abstract][Full Text] [Related]
23. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. Epstein JI; Paull G; Eggleston JC; Walsh PC J Urol; 1986 Oct; 136(4):837-9. PubMed ID: 3761442 [TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06. Pilepich MV; Krall JM; Sause WT; Johnson RJ; Russ HH; Hanks GE; Perez CA; Zinninger M; Martz KL Int J Radiat Oncol Biol Phys; 1987 Mar; 13(3):339-49. PubMed ID: 3558026 [TBL] [Abstract][Full Text] [Related]
25. The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma. Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Papapoulos SE; Hamdy NA J Urol; 1996 Jul; 156(1):122-6. PubMed ID: 8648772 [TBL] [Abstract][Full Text] [Related]
26. [Clinical assessments on pre-treatment prognostic factors in 138 patients with advanced prostatic carcinoma (stage D2)]. Kato M; Okada K; Yamashina M; Tohma T; Ishiwata D; Higashi Y; Ohwada F Hinyokika Kiyo; 1993 Feb; 39(2):131-4. PubMed ID: 8465686 [TBL] [Abstract][Full Text] [Related]
27. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Tamimi Y; van der Poel HG; Karthaus HF; Debruyne FM; Schalken JA Br J Cancer; 1996 Aug; 74(4):573-8. PubMed ID: 8761372 [TBL] [Abstract][Full Text] [Related]
28. Prognostic variables in patients with prostate cancer: influence of blood group ABO (H), the Rhesus system, age, differentiation, tumour stage and metastases. Kvist E; Krogh J; Hjortberg P Int Urol Nephrol; 1992; 24(4):417-23. PubMed ID: 1459817 [TBL] [Abstract][Full Text] [Related]
30. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence. Jones TD; Koch MO; Lin H; Cheng L BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440 [TBL] [Abstract][Full Text] [Related]
31. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. Cantrell BB; DeKlerk DP; Eggleston JC; Boitnott JK; Walsh PC J Urol; 1981 Apr; 125(4):516-20. PubMed ID: 7218450 [TBL] [Abstract][Full Text] [Related]
32. [Onset of and survival in adenocarcinoma of the prostate. Analysis of 48 consecutive cases studied over 10 years]. Goodman CM; Chisholm GD Arch Esp Urol; 1989; 42 Suppl 2():117-23. PubMed ID: 2700880 [TBL] [Abstract][Full Text] [Related]
33. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study. Shou J; Zhang Q; Wang S; Zhang D Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722 [TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346 [TBL] [Abstract][Full Text] [Related]
35. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Fuks Z; Leibel SA; Wallner KE; Begg CB; Fair WR; Anderson LL; Hilaris BS; Whitmore WF Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):537-47. PubMed ID: 1869452 [TBL] [Abstract][Full Text] [Related]
36. [Prostatic carcinoma: histoprognosis, prognostic value of Gleason's index]. Saint-André JP; Rousselet MC; Six P; Bertrand G; Soret JY Bull Cancer; 1985; 72(5):414-22. PubMed ID: 4074910 [TBL] [Abstract][Full Text] [Related]
37. [Stage M1b prostatic adenocarcinoma: prognostic factors, value of bone scintigraphy]. Rattier C; Rossi D; Coulange C; Rampal M; Serment G Prog Urol; 1994 Dec; 4(6):984-99. PubMed ID: 7874187 [TBL] [Abstract][Full Text] [Related]
38. Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment. Androulakakis PA; Schneider HM; Jacobi GH; Hohenfellner R Br J Urol; 1986 Apr; 58(2):153-6. PubMed ID: 3697629 [TBL] [Abstract][Full Text] [Related]
39. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate). Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480 [TBL] [Abstract][Full Text] [Related]
40. Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma. Yildiz E; Ayan S; Goze F; Gokce G; Gultekin EY BJU Int; 2008 Mar; 101(6):758-64. PubMed ID: 18070177 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]